Survivin inhibition by an interacting recombinant peptide, derived from the human ferritin heavy chain, impedes tumor cell growth (Q39377777)

11 September 2017

title

Survivin inhibition by an interacting recombinant peptide, derived from the human ferritin heavy chain, impedes tumor cell growth (English)

1 reference

11 September 2017

1 reference

Astrid Weiss

1

1 reference

11 September 2017

Boris Brill

2

1 reference

11 September 2017

Corina Borghouts

3

1 reference

11 September 2017

Natalia Delis

4

1 reference

11 September 2017

Laura Mack

5

1 reference

11 September 2017

Bernd Groner

6

1 reference

11 September 2017

publication date

18 March 2012

1 reference

Journal of Cancer Research and Clinical Oncology

11 September 2017

published in

1 reference

11 September 2017

volume

138

1 reference

11 September 2017

issue

7

1 reference

11 September 2017

page(s)

1205-1220

1 reference

https://scigraph.springernature.com/pub.10.1007/s00432-012-1195-1

11 September 2017

exact match

0 references

cites work

Regulation of neuronal ferritin heavy chain, a new player in opiate-induced chemokine dysfunction

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

New wirings in the survivin networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Survivin and IAP proteins in cell-death mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Selection and characterization of large collections of peptide aptamers through optimized yeast two-hybrid procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Monomeric recombinant peptide aptamers are required for efficient intracellular uptake and target inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

The intracellular delivery of a recombinant peptide derived from the acidic domain of PIAS3 inhibits STAT3 transactivation and induces tumor cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

The mitotic regulator Survivin binds as a monomer to its functional interactor Borealin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Histone deacetylase inhibitor belinostat represses survivin expression through reactivation of transforming growth factor beta (TGFbeta) receptor II leading to cancer cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Current prospects for RNA interference-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

X-linked inhibitor of apoptosis protein as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Genome remodelling in a basal-like breast cancer metastasis and xenograft

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Reversing cancer from inside and out: oncogene addiction, cellular senescence, and the angiogenic switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Early embryonic lethality of H ferritin gene deletion in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Survivin, a cancer target with an emerging role in normal adult tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Balancing acts: molecular control of mammalian iron metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Cellular regulation and molecular interactions of the ferritins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Drugs, their targets and the nature and number of drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Ferritin for the clinician

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

IAP-targeted therapies for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Chemokine CXCL12 induces binding of ferritin heavy chain to the chemokine receptor CXCR4, alters CXCR4 signaling, and induces phosphorylation and nuclear translocation of ferritin heavy chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Binding and uptake of H-ferritin are mediated by human transferrin receptor-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Is survivin the potential Achilles' heel of cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Principles of cancer therapy: oncogene and non-oncogene addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Cancer gene therapy using a survivin mutant adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Direct inhibition of the NOTCH transcription factor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Induction of apoptosis by survivin silencing through siRNA delivery in a human breast cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Monitoring the interference of protein-protein interactions in vivo by bimolecular fluorescence complementation: the DnaK case.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Study and selection of in vivo protein interactions by coupling bimolecular fluorescence complementation and flow cytometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Identification of a small-molecule inhibitor of the interaction between Survivin and Smac/DIABLO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

The druggable genome: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Survivin: a new target for anti-cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Cell signaling in space and time: where proteins come together and when they're apart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Exploiting the balance between life and death: targeted cancer therapy and "oncogenic shock".

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Promises and challenges in developing RNAi as a research tool and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Dynamic interactions of proteins in complex networks: a more structured view.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Survivin mediates targeting of the chromosomal passenger complex to the centromere and midbody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Gambogic acid, a potent inhibitor of survivin, reverses docetaxel resistance in gastric cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Ferritin H induction by histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Cancer cells survive with survivin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable Survivin antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Bio-inspired, bioengineered and biomimetic drug delivery carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1195-1

High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma

21 January 2018

1 reference

12 December 2020

N-terminal deletion effects of human survivin on dimerization and binding to Smac/DIABLO in vitro

1 reference

12 December 2020

Our changing view of the genomic landscape of cancer

1 reference

12 December 2020

Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo.

1 reference

12 December 2020

Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis

1 reference

12 December 2020

10.1007/S00432-012-1195-1

Identifiers

DOI

1 reference

11 September 2017

1 reference